Emerging and investigational drugs for premature ejaculation

Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation whic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational andrology and urology 2016-08, Vol.5 (4), p.487-501
1. Verfasser: McMahon, Chris G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 501
container_issue 4
container_start_page 487
container_title Translational andrology and urology
container_volume 5
creator McMahon, Chris G
description Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with α1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.
doi_str_mv 10.21037/tau.2016.04.02
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5001989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1822468843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-4d7958351e865edd24e60dea08b7b44f163c47eb6ef07e8c965f634eb90d35f3</originalsourceid><addsrcrecordid>eNpVkMtLw0AQxhdRbKk9e5McvSTdVza7IIKU-oCCl96XTXYSt-RRd5OC_72x1VJPMzDffDPfD6FbghNKMMsWvRkSiolIME8wvUBTSimLuVDk8qyfoHkIW4wxoUxyQa7RhGYiHed0ih5WDfjKtVVkWhu5dg-hd5XpXdeaOrJ-qEJUdj7aeWhMP3iIYGuKoT4obtBVaeoA8986Q5vn1Wb5Gq_fX96WT-u4YIr1MbeZSiVLCUiRgrWUg8AWDJZ5lnNeEsEKnkEuoMQZyEKJtBSMQ66wZWnJZujxaLsb8gZsAW3vTa133jXGf-nOOP1_0roPXXV7nY6ZlVSjwf2vge8-hzGhblwooK5NC90QNJGUciElZ6N0cZQWvgvBQ3k6Q7A-UNcjdf1DXWOuMR037s6_O-n_GLNvtmd_LA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1822468843</pqid></control><display><type>article</type><title>Emerging and investigational drugs for premature ejaculation</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>McMahon, Chris G</creator><creatorcontrib>McMahon, Chris G</creatorcontrib><description>Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with α1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.</description><identifier>ISSN: 2223-4691</identifier><identifier>ISSN: 2223-4683</identifier><identifier>EISSN: 2223-4691</identifier><identifier>DOI: 10.21037/tau.2016.04.02</identifier><identifier>PMID: 27652222</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Review</subject><ispartof>Translational andrology and urology, 2016-08, Vol.5 (4), p.487-501</ispartof><rights>2016 Translational Andrology and Urology. All rights reserved. 2016 Translational Andrology and Urology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-4d7958351e865edd24e60dea08b7b44f163c47eb6ef07e8c965f634eb90d35f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001989/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001989/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27652222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McMahon, Chris G</creatorcontrib><title>Emerging and investigational drugs for premature ejaculation</title><title>Translational andrology and urology</title><addtitle>Transl Androl Urol</addtitle><description>Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with α1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.</description><subject>Review</subject><issn>2223-4691</issn><issn>2223-4683</issn><issn>2223-4691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkMtLw0AQxhdRbKk9e5McvSTdVza7IIKU-oCCl96XTXYSt-RRd5OC_72x1VJPMzDffDPfD6FbghNKMMsWvRkSiolIME8wvUBTSimLuVDk8qyfoHkIW4wxoUxyQa7RhGYiHed0ih5WDfjKtVVkWhu5dg-hd5XpXdeaOrJ-qEJUdj7aeWhMP3iIYGuKoT4obtBVaeoA8986Q5vn1Wb5Gq_fX96WT-u4YIr1MbeZSiVLCUiRgrWUg8AWDJZ5lnNeEsEKnkEuoMQZyEKJtBSMQ66wZWnJZujxaLsb8gZsAW3vTa133jXGf-nOOP1_0roPXXV7nY6ZlVSjwf2vge8-hzGhblwooK5NC90QNJGUciElZ6N0cZQWvgvBQ3k6Q7A-UNcjdf1DXWOuMR037s6_O-n_GLNvtmd_LA</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>McMahon, Chris G</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201608</creationdate><title>Emerging and investigational drugs for premature ejaculation</title><author>McMahon, Chris G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-4d7958351e865edd24e60dea08b7b44f163c47eb6ef07e8c965f634eb90d35f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McMahon, Chris G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational andrology and urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McMahon, Chris G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging and investigational drugs for premature ejaculation</atitle><jtitle>Translational andrology and urology</jtitle><addtitle>Transl Androl Urol</addtitle><date>2016-08</date><risdate>2016</risdate><volume>5</volume><issue>4</issue><spage>487</spage><epage>501</epage><pages>487-501</pages><issn>2223-4691</issn><issn>2223-4683</issn><eissn>2223-4691</eissn><abstract>Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with α1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>27652222</pmid><doi>10.21037/tau.2016.04.02</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2223-4691
ispartof Translational andrology and urology, 2016-08, Vol.5 (4), p.487-501
issn 2223-4691
2223-4683
2223-4691
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5001989
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Review
title Emerging and investigational drugs for premature ejaculation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A25%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20and%20investigational%20drugs%20for%20premature%20ejaculation&rft.jtitle=Translational%20andrology%20and%20urology&rft.au=McMahon,%20Chris%20G&rft.date=2016-08&rft.volume=5&rft.issue=4&rft.spage=487&rft.epage=501&rft.pages=487-501&rft.issn=2223-4691&rft.eissn=2223-4691&rft_id=info:doi/10.21037/tau.2016.04.02&rft_dat=%3Cproquest_pubme%3E1822468843%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1822468843&rft_id=info:pmid/27652222&rfr_iscdi=true